JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Development and Validation of a Predictive Nomogram for Myelosuppression Risk in Chronic Hepatitis B Patients Treated with Peginterferon

  • 0Department of Infectious Diseases, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi Province, 330006, People's Republic of China.
Infection and Drug Resistance +

|

April 14, 2025

|

April 14, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

This study identified lower body mass index, white blood cell counts, and globulin levels, along with higher serum creatinine, as key risk factors for peginterferon-induced myelosuppression in chronic hepatitis B patients. A predictive nomogram effectively identifies individuals at high risk for this side effect.

Area Of Science

  • Hepatology
  • Pharmacology
  • Medical Statistics

Background

  • Peginterferon (Peg-IFN) is a standard treatment for chronic hepatitis B (CHB).
  • Myelosuppression is a significant side effect of Peg-IFN therapy in CHB patients.
  • Identifying patients at risk for myelosuppression is crucial for treatment management.

Purpose Of The Study

  • To identify independent risk factors associated with Peg-IFN-induced myelosuppression in CHB patients.
  • To develop and validate a predictive nomogram for myelosuppression risk in Peg-IFN-treated CHB patients.

Main Methods

  • A retrospective case-control study involving 312 CHB patients treated with Peg-IFN.
  • Patients were divided into training (n=153), test (n=55), and validation (n=104) cohorts.
  • Logistic regression analysis identified risk factors; a nomogram was constructed and validated using ROC curves, Hosmer-Lemeshow tests, calibration curves, and decision curve analysis (DCA).

Main Results

  • Independent risk factors for myelosuppression included lower body mass index (BMI), white blood cell (WBC) counts, and globulin (GLB) levels, and higher serum creatinine (SCR) levels.
  • The predictive nomogram demonstrated good predictive accuracy with Area Under the Curve (AUC) values of 0.824 (training), 0.812 (test), and 0.870 (validation).
  • The nomogram showed good calibration and clinical utility across all cohorts.

Conclusions

  • Lower BMI, WBC, GLB, and higher SCR are independent predictors of Peg-IFN-induced myelosuppression in CHB.
  • The developed nomogram accurately predicts myelosuppression risk in Peg-IFN-treated CHB patients.
  • This tool can aid in early identification and management of myelosuppression, optimizing Peg-IFN therapy.

Keywords: